Dataset Information

Recovery of Resistant Alopecia Areata Treated with Tofacitinib: An 8-Year-Old Child's Case Report.

ABSTRACT: Tofacitinib has been reported to activity in the recovery of alopecia areata (AA) in several reports, mainly from Western countries. We report the case of a young Indian boy with resistant AA who was treated with tofacitinib-based therapy. Improvements in terms of hair regrowth were observed within 6-8 weeks of treatment with oral tofacitinib 2.5 mg BID tablets, and the hair regrowth was nearly complete by 5 months. There were no associated side effects and the treatment with tofacitinib was well-tolerated.

SUBMITTER: Bhokare A

PROVIDER: S-EPMC9447467 | biostudies-literature | 2022 Jul-Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Recovery of Resistant Alopecia Areata Treated with Tofacitinib: An 8-Year-Old Child's Case Report.

Bhokare Anil A

International journal of trichology 20220716 4

Tofacitinib has been reported to activity in the recovery of alopecia areata (AA) in several reports, mainly from Western countries. We report the case of a young Indian boy with resistant AA who was treated with tofacitinib-based therapy. Improvements in terms of hair regrowth were observed within 6-8 weeks of treatment with oral tofacitinib 2.5 mg BID tablets, and the hair regrowth was nearly complete by 5 months. There were no associated side effects and the treatment with tofacitinib was wel ...[more]

PMID: 36081438

Similar Datasets

Project description:BackgroundAlopecia areata (AA) is an autoimmune disease characterized by hair loss mediated by CD8+ T cells. There are no reliably effective therapies for AA. Based on recent developments in the understanding of the pathomechanism of AA, JAK inhibitors appear to be a therapeutic option; however, their efficacy for the treatment of AA has not been systematically examined.MethodsThis was a 2-center, open-label, single-arm trial using the pan-JAK inhibitor, tofacitinib citrate, for AA with >50% scalp hair loss, alopecia totalis (AT), and alopecia universalis (AU). Tofacitinib (5 mg) was given twice daily for 3 months. Endpoints included regrowth of scalp hair, as assessed by the severity of alopecia tool (SALT), duration of hair growth after completion of therapy, and disease transcriptome.ResultsOf 66 subjects treated, 32% experienced 50% or greater improvement in SALT score. AA and ophiasis subtypes were more responsive than AT and AU subtypes. Shorter duration of disease and histological peribulbar inflammation on pretreatment scalp biopsies were associated with improvement in SALT score. Drug cessation resulted in disease relapse in 8.5 weeks. Adverse events were limited to grade I and II infections. An AA responsiveness to JAK/STAT inhibitors score was developed to segregate responders and nonresponders, and the previously developed AA disease activity index score tracked response to treatment.ConclusionsAt the dose and duration studied, tofacitinib is a safe and effective treatment for severe AA, though it does not result in a durable response. Transcriptome changes reveal unexpected molecular complexity within the disease.Trial registrationClinicalTrials.gov NCT02197455 and NCT02312882.FundingThis work was supported by the US Department of Veterans Affairs Office of Research and Development, National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institutes of Health grant R01 AR47223 and U01 AR67173, the National Psoriasis Foundation, the Swedish Society of Medicine, the Fernström Foundation, the Locks of Love Foundation, the National Alopecia Areata Foundation, and the Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research.

Dataset Information

Recovery of Resistant Alopecia Areata Treated with Tofacitinib: An 8-Year-Old Child's Case Report.

Publications

Recovery of Resistant Alopecia Areata Treated with Tofacitinib: An 8-Year-Old Child's Case Report.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets